35552711000001106: Kanjinti 150mg powder for concentrate for solution for infusion vials (Amgen Ltd) (product)

SNOMED CT Concept\Pharmaceutical / biologic product\...

\UK product\Actual medicinal product\Kanjinti 150mg powder for concentrate for solution for infusion vials (Amgen Ltd)
\UK product\Virtual medicinal product\Product containing precisely trastuzumab 150 milligram/1 vial powder for conventional release solution for injection\Kanjinti 150mg powder for concentrate for solution for infusion vials (Amgen Ltd)
\UK product\Virtual therapeutic moiety\Trastuzumab\Product containing only trastuzumab in parenteral dose form (medicinal product form)\Product containing precisely trastuzumab 150 milligram/1 vial powder for conventional release solution for injection\Kanjinti 150mg powder for concentrate for solution for infusion vials (Amgen Ltd)
\UK product\Virtual therapeutic moiety\Trastuzumab\Product containing precisely trastuzumab 150 milligram/1 vial powder for conventional release solution for injection\Kanjinti 150mg powder for concentrate for solution for infusion vials (Amgen Ltd)
\UK product\Trade family\Kanjinti\Kanjinti 150mg powder for concentrate for solution for infusion vials (Amgen Ltd)

\Medicinal product\Medicinal product categorized by disposition\Product containing enzyme inhibitor\Product containing transferase inhibitor\Product containing phosphotransferase inhibitor\Product containing protein kinase inhibitor\Medicinal product containing epidermal growth factor receptor antagonist and acting as antineoplastic agent (product)\Product containing trastuzumab\Trastuzumab\Product containing only trastuzumab in parenteral dose form (medicinal product form)\Product containing precisely trastuzumab 150 milligram/1 vial powder for conventional release solution for injection\Kanjinti 150mg powder for concentrate for solution for infusion vials (Amgen Ltd)
\Medicinal product\Medicinal product categorized by disposition\Product containing enzyme inhibitor\Product containing transferase inhibitor\Product containing phosphotransferase inhibitor\Product containing protein kinase inhibitor\Medicinal product containing epidermal growth factor receptor antagonist and acting as antineoplastic agent (product)\Product containing trastuzumab\Trastuzumab\Product containing precisely trastuzumab 150 milligram/1 vial powder for conventional release solution for injection\Kanjinti 150mg powder for concentrate for solution for infusion vials (Amgen Ltd)
\Medicinal product\Medicinal product categorized by disposition\Product containing enzyme inhibitor\Product containing transferase inhibitor\Product containing phosphotransferase inhibitor\Product containing protein kinase inhibitor\Medicinal product containing epidermal growth factor receptor antagonist and acting as antineoplastic agent (product)\Product containing trastuzumab\Product containing trastuzumab in parenteral dose form (medicinal product form)\Product containing only trastuzumab in parenteral dose form (medicinal product form)\Product containing precisely trastuzumab 150 milligram/1 vial powder for conventional release solution for injection\Kanjinti 150mg powder for concentrate for solution for infusion vials (Amgen Ltd)
\Medicinal product\Medicinal product categorized by disposition\Product containing immunomodulator\Product containing trastuzumab\Trastuzumab\Product containing only trastuzumab in parenteral dose form (medicinal product form)\Product containing precisely trastuzumab 150 milligram/1 vial powder for conventional release solution for injection\Kanjinti 150mg powder for concentrate for solution for infusion vials (Amgen Ltd)
\Medicinal product\Medicinal product categorized by disposition\Product containing immunomodulator\Product containing trastuzumab\Trastuzumab\Product containing precisely trastuzumab 150 milligram/1 vial powder for conventional release solution for injection\Kanjinti 150mg powder for concentrate for solution for infusion vials (Amgen Ltd)
\Medicinal product\Medicinal product categorized by disposition\Product containing immunomodulator\Product containing trastuzumab\Product containing trastuzumab in parenteral dose form (medicinal product form)\Product containing only trastuzumab in parenteral dose form (medicinal product form)\Product containing precisely trastuzumab 150 milligram/1 vial powder for conventional release solution for injection\Kanjinti 150mg powder for concentrate for solution for infusion vials (Amgen Ltd)
\Medicinal product\Medicinal product categorized by structure\Product containing nitrogen and/or nitrogen compound (product)\Product containing polypeptide\Product containing protein\Product containing antibody\Product containing monoclonal antibody\Medicinal product containing monoclonal antibody and acting as antineoplastic agent (product)\Product containing trastuzumab\Trastuzumab\Product containing only trastuzumab in parenteral dose form (medicinal product form)\Product containing precisely trastuzumab 150 milligram/1 vial powder for conventional release solution for injection\Kanjinti 150mg powder for concentrate for solution for infusion vials (Amgen Ltd)
\Medicinal product\Medicinal product categorized by structure\Product containing nitrogen and/or nitrogen compound (product)\Product containing polypeptide\Product containing protein\Product containing antibody\Product containing monoclonal antibody\Medicinal product containing monoclonal antibody and acting as antineoplastic agent (product)\Product containing trastuzumab\Trastuzumab\Product containing precisely trastuzumab 150 milligram/1 vial powder for conventional release solution for injection\Kanjinti 150mg powder for concentrate for solution for infusion vials (Amgen Ltd)
\Medicinal product\Medicinal product categorized by structure\Product containing nitrogen and/or nitrogen compound (product)\Product containing polypeptide\Product containing protein\Product containing antibody\Product containing monoclonal antibody\Medicinal product containing monoclonal antibody and acting as antineoplastic agent (product)\Product containing trastuzumab\Product containing trastuzumab in parenteral dose form (medicinal product form)\Product containing only trastuzumab in parenteral dose form (medicinal product form)\Product containing precisely trastuzumab 150 milligram/1 vial powder for conventional release solution for injection\Kanjinti 150mg powder for concentrate for solution for infusion vials (Amgen Ltd)
\Medicinal product\Medicinal product categorized by therapeutic role\Medicinal product acting as antineoplastic agent (product)\Medicinal product containing monoclonal antibody and acting as antineoplastic agent (product)\Product containing trastuzumab\Trastuzumab\Product containing only trastuzumab in parenteral dose form (medicinal product form)\Product containing precisely trastuzumab 150 milligram/1 vial powder for conventional release solution for injection\Kanjinti 150mg powder for concentrate for solution for infusion vials (Amgen Ltd)
\Medicinal product\Medicinal product categorized by therapeutic role\Medicinal product acting as antineoplastic agent (product)\Medicinal product containing monoclonal antibody and acting as antineoplastic agent (product)\Product containing trastuzumab\Trastuzumab\Product containing precisely trastuzumab 150 milligram/1 vial powder for conventional release solution for injection\Kanjinti 150mg powder for concentrate for solution for infusion vials (Amgen Ltd)
\Medicinal product\Medicinal product categorized by therapeutic role\Medicinal product acting as antineoplastic agent (product)\Medicinal product containing monoclonal antibody and acting as antineoplastic agent (product)\Product containing trastuzumab\Product containing trastuzumab in parenteral dose form (medicinal product form)\Product containing only trastuzumab in parenteral dose form (medicinal product form)\Product containing precisely trastuzumab 150 milligram/1 vial powder for conventional release solution for injection\Kanjinti 150mg powder for concentrate for solution for infusion vials (Amgen Ltd)
\Medicinal product\Medicinal product categorized by therapeutic role\Medicinal product acting as antineoplastic agent (product)\Medicinal product containing epidermal growth factor receptor antagonist and acting as antineoplastic agent (product)\Product containing trastuzumab\Trastuzumab\Product containing only trastuzumab in parenteral dose form (medicinal product form)\Product containing precisely trastuzumab 150 milligram/1 vial powder for conventional release solution for injection\Kanjinti 150mg powder for concentrate for solution for infusion vials (Amgen Ltd)
\Medicinal product\Medicinal product categorized by therapeutic role\Medicinal product acting as antineoplastic agent (product)\Medicinal product containing epidermal growth factor receptor antagonist and acting as antineoplastic agent (product)\Product containing trastuzumab\Trastuzumab\Product containing precisely trastuzumab 150 milligram/1 vial powder for conventional release solution for injection\Kanjinti 150mg powder for concentrate for solution for infusion vials (Amgen Ltd)
\Medicinal product\Medicinal product categorized by therapeutic role\Medicinal product acting as antineoplastic agent (product)\Medicinal product containing epidermal growth factor receptor antagonist and acting as antineoplastic agent (product)\Product containing trastuzumab\Product containing trastuzumab in parenteral dose form (medicinal product form)\Product containing only trastuzumab in parenteral dose form (medicinal product form)\Product containing precisely trastuzumab 150 milligram/1 vial powder for conventional release solution for injection\Kanjinti 150mg powder for concentrate for solution for infusion vials (Amgen Ltd)
\Medicinal product\Product manufactured as parenteral dose form\Product containing trastuzumab in parenteral dose form (medicinal product form)\Product containing only trastuzumab in parenteral dose form (medicinal product form)\Product containing precisely trastuzumab 150 milligram/1 vial powder for conventional release solution for injection\Kanjinti 150mg powder for concentrate for solution for infusion vials (Amgen Ltd)

Status: current, Not sufficiently defined by necessary conditions definition status. Date: 13-Jun 2018. Module: SNOMED CT United Kingdom drug extension module

Descriptions:

Id Description Lang Type Status Case? Module

107166201000001114 Kanjinti 150mg powder for concentrate for solution for infusion vials (Amgen Ltd) (product) en Fully specified name Active Entire term case sensitive SNOMED CT United Kingdom drug extension module

107166301000001117 Kanjinti 150mg powder for concentrate for solution for infusion vials (Amgen Ltd) en Synonym Active Entire term case sensitive SNOMED CT United Kingdom drug extension module

Expanded Value Set

Outbound Relationships	Type	Target	Active	Characteristic	Refinability	Group	Values
Kanjinti 150mg powder for concentrate for solution for infusion vials (Amgen Ltd)	Has excipient	Excipient not declared	true	Inferred relationship	Existential restriction modifier
Kanjinti 150mg powder for concentrate for solution for infusion vials (Amgen Ltd)	VMP prescribing status (attribute)	Caution - AMP level prescribing advised	true	Inferred relationship	Existential restriction modifier
Kanjinti 150mg powder for concentrate for solution for infusion vials (Amgen Ltd)	Has NHS dm+d (dictionary of medicines and devices) controlled drug category	Controlled drug category No Controlled Drug Status	true	Inferred relationship	Existential restriction modifier
Kanjinti 150mg powder for concentrate for solution for infusion vials (Amgen Ltd)	Has NHS dm+d (dictionary of medicines and devices) AMP (actual medicinal product) availability restriction indicator	NHS dm+d (dictionary of medicines and devices) AMP (actual medicinal product) availability restriction none	true	Inferred relationship	Existential restriction modifier
Kanjinti 150mg powder for concentrate for solution for infusion vials (Amgen Ltd)	Has NHS dm+d (dictionary of medicines and devices) additional monitoring indicator	EMA (European Medicines Agency) monitoring	true	Inferred relationship	Existential restriction modifier
Kanjinti 150mg powder for concentrate for solution for infusion vials (Amgen Ltd)	Is a	Product containing precisely trastuzumab 150 milligram/1 vial powder for conventional release solution for injection	true	Inferred relationship	Existential restriction modifier
Kanjinti 150mg powder for concentrate for solution for infusion vials (Amgen Ltd)	Has active ingredient	Trastuzumab	false	Inferred relationship	Existential restriction modifier
Kanjinti 150mg powder for concentrate for solution for infusion vials (Amgen Ltd)	Has manufactured dose form	Powder for infusion solution	false	Inferred relationship	Existential restriction modifier
Kanjinti 150mg powder for concentrate for solution for infusion vials (Amgen Ltd)	VMP prescribing status (attribute)	VMP valid as a prescribable product	false	Inferred relationship	Existential restriction modifier
Kanjinti 150mg powder for concentrate for solution for infusion vials (Amgen Ltd)	VMP non-availability indicator	Available	true	Inferred relationship	Existential restriction modifier
Kanjinti 150mg powder for concentrate for solution for infusion vials (Amgen Ltd)	Has specific active ingredient	Trastuzumab	true	Inferred relationship	Existential restriction modifier
Kanjinti 150mg powder for concentrate for solution for infusion vials (Amgen Ltd)	Has dispensed dose form	Powder for infusion solution	false	Inferred relationship	Existential restriction modifier
Kanjinti 150mg powder for concentrate for solution for infusion vials (Amgen Ltd)	Has excipient	Polysorbate	false	Inferred relationship	Existential restriction modifier
Kanjinti 150mg powder for concentrate for solution for infusion vials (Amgen Ltd)	Is a	Actual medicinal product	true	Inferred relationship	Existential restriction modifier
Kanjinti 150mg powder for concentrate for solution for infusion vials (Amgen Ltd)	Is a	Kanjinti	true	Inferred relationship	Existential restriction modifier
Kanjinti 150mg powder for concentrate for solution for infusion vials (Amgen Ltd)	Has dispensed dose form	Powder for conventional release solution for infusion	true	Inferred relationship	Existential restriction modifier
Kanjinti 150mg powder for concentrate for solution for infusion vials (Amgen Ltd)	Has manufactured dose form	Powder for conventional release solution for injection	true	Inferred relationship	Existential restriction modifier

Inbound Relationships	Type	Active	Source	Characteristic	Refinability	Group
Kanjinti 150mg powder for concentrate for solution for infusion vials (Amgen Ltd) 1 vial	Has AMP	True	Kanjinti 150mg powder for concentrate for solution for infusion vials (Amgen Ltd)	Inferred relationship	Existential restriction modifier

This concept is not in any reference sets

Back to Start

Id	Description	Lang	Type	Status	Case?	Module
107166201000001114	Kanjinti 150mg powder for concentrate for solution for infusion vials (Amgen Ltd) (product)	en	Fully specified name	Active	Entire term case sensitive	SNOMED CT United Kingdom drug extension module
107166301000001117	Kanjinti 150mg powder for concentrate for solution for infusion vials (Amgen Ltd)	en	Synonym	Active	Entire term case sensitive	SNOMED CT United Kingdom drug extension module